

SPL7013 Nasal Spray Australia Update

Melbourne, Australia; 18 October 2024: Starpharma (ASX: SPL, OTCQX: SPHRY), an innovative biotechnology company with two decades of experience in advancing dendrimer technology from the lab to the patient, today announces that, after careful consideration, we have withdrawn the application for marketing authorisation of the SPL7013 Nasal Spray in Australia.

Starpharma CEO Cheryl Maley commented:

"We have withdrawn the application for inclusion of the SPL7013 Nasal Spray in the Australian Register of Therapeutic Goods (ARTG), which would have allowed marketing in Australia. The decision comes after a more than three-year application and TGA review process that has consumed significant internal resources, which will now be directed towards our other strategic priorities and high-priority DEP® platform projects.

"We have not made this decision lightly and have thoroughly explored alternative options based on the current status of the application and ongoing engagement with the regulator. After careful consideration and external regulatory legal advice, the Board and management have determined that withdrawing the application at this time to focus on our strategic priorities is in the best interest of Starpharma and our shareholders.

"The SPL7013 Nasal Spray is registered in over 35 countries, including the UK and Europe, and we will continue to market the product in these regions. We have ongoing marketing campaigns in these areas aimed at boosting revenue, aligning with our third strategic objective of long-term sustainability.

"Considering our strategic priorities announced in May 2024, we believe the withdrawal of the application and focussing on our strategic priorities is the most appropriate course of action at this time. We are confident that achieving the outcomes outlined in our strategic priorities will ensure successful outcomes for patients and shareholders.

"Our top priority is the licensing of our unique DEP technology platform, and our team needs to remain focused on achieving this outcome for our shareholders. Additionally, we remain focused on advancing our partnerships and our internal radiopharmaceuticals program towards a clinical trial is a priority for the group."

About Starpharma

Starpharma ASX: SPL, OTCQX: SPHRY) is an innovative biotechnology company with two decades of experience in advancing dendrimer technology from the lab to the patient. Our mission is to help patients with significant illnesses, such as cancer, achieve improved health outcomes and quality of life through the application of our unique dendrimer technology.

Dendrimers are precise, synthetically manufactured, nanoscale molecules. Their unique properties—including their size, structure, high degree of branching, polyvalency, and water solubility—are advantageous in medical and pharmaceutical applications.

Starpharma's portfolio of dendrimer-based products includes three clinical-stage DEP® (dendrimer enhanced product) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over-the-counter (OTC) products.

For more information about Starpharma, visit www.starpharma.com or connect with Starpharma on [LinkedIn](#).

**WE Communications**

Hannah Howlett
+61 450 648 064
WE-AUStarPharma@we-worldwide.com

Starpharma Holdings Limited

Cheryl Maley, Chief Executive Officer
Justin Cahill, CFO and Company Secretary
+61 3 8532 2704
investor.relations@starpharma.com
4-6 Southampton Crescent
Abbotsford Vic 3067

Disclosure

This ASX Announcement was authorised for release by the Chair, Mr Rob Thomas.

Forward-Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other authorities' requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. Clinical case studies and other clinical information given in this document are given for illustrative purposes only and are not necessarily a guide to product performance and no representation or warranty is made by any person as to the likelihood of achievement or reasonableness of future results. Nothing contained in this document, nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or the future performance of any Starpharma product.